AKR1C3 as a target in castrate resistant prostate cancer

被引：121

作者：

Adeniji, Adegoke O. ^{[1
]}

Chen, Mo ^{[1
]}

Penning, Trevor M. ^{[1
,2
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Ctr Excellence Environm Toxicol, Philadelphia, PA 19104 USA

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 2013年 / 137卷

关键词：

Type 5 17 beta-hydroxysteroid dehydrogenase; Prostaglandin F synthase; Prostate cancer; Androgens; Nonsteroidal anti-inflammatory drugs; KETO REDUCTASE SUPERFAMILY; CINNAMIC ACID-DERIVATIVES; PROSTAGLANDIN-F SYNTHASE; ANDROGEN RECEPTOR; SELECTIVE INHIBITORS; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; ABIRATERONE ACETATE; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL;

D O I：

10.1016/j.jsbmb.2013.05.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Aberrant androgen receptor (AR) activation is the major driver of castrate resistant prostate cancer (CRPC). CRPC is ultimately fatal and more therapeutic agents are needed to treat this disease. Compounds that target the androgen axis by inhibiting androgen biosynthesis and or AR signaling are potential candidates for use in CRPC treatment and are currently being pursued aggressively. Aldo-keto reductase 10 (AKR1C3) plays a pivotal role in androgen biosynthesis within the prostate. It catalyzes the 17-ketoreduction of weak androgen precursors to give testosterone and 5 alpha-dihydrotestosterone. AKR1C3 expression and activity has been implicated in the development of CRPC, making it a rational target. Selective inhibition of AKR1C3 will be important, however, due to the presence of closely related isoforms. AKR1C1 and AKR1C2 that are also involved in androgen inactivation. We examine the evidence that supports the vital role of AKR1C3 in CRPC and recent developments in the discovery of potent and selective AKR1C3 inhibitors. This article is part of a Special Issue entitled 'CSR 2013'. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：136 / 149

页数：14

共 80 条

[21] Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer [J].

Chen, Mo ;

Adeniji, Adegoke O. ;

Twenter, Barry M. ;

Winkler, Jeffrey D. ;

Christianson, David W. ;

Penning, Trevor M. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (10) :3492-3497

[22] AKR1C Isoforms Represent a Novel Cellular Target for Jasmonates alongside Their Mitochondrial-Mediated Effects [J].

Davies, Nicholas J. ;

Hayden, Rachel E. ;

Simpson, Paul J. ;

Birtwistle, Jane ;

Mayer, Katarina ;

Ride, Jonathan P. ;

Bunce, Chris M. .

CANCER RESEARCH, 2009, 69 (11) :4769-4775

[23] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[24]

Desmond JC, 2003, CANCER RES, V63, P505

[25] Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 [J].

DeVore, Natasha M. ;

Scott, Emily E. .

NATURE, 2012, 482 (7383) :116-U149

[26] PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3 [J].

Downs, Tracy M. ;

Burton, Douglas W. ;

Araiza, Flavio L. ;

Hastings, Randolph H. ;

Deftos, Leonard J. .

CANCER LETTERS, 2011, 306 (01) :52-59

[27] Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan [J].

Dozmorov, Mikhail G. ;

Azzarello, Joseph T. ;

Wren, Jonathan D. ;

Fung, Kar-Ming ;

Yang, Qing ;

Davis, Jeffrey S. ;

Hurst, Robert E. ;

Culkin, Daniel J. ;

Penning, Trevor M. ;

Lin, Hsueh-Kung .

BMC CANCER, 2010, 10

[28] MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. [J].

Efstathiou, E. ;

Titus, M. A. ;

Tsavachidou, D. ;

Hoang, A. ;

Karlou, M. ;

Wen, S. ;

Troncoso, P. ;

Ashe, R. ;

Berman, C. J. ;

Mohler, J. ;

Logothetis, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[29] Selective Inhibition of Human Type-5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) by Baccharin, a Component of Brazilian Propolis [J].

Endo, Satoshi ;

Matsunaga, Toshiyuki ;

Kanamori, Ayano ;

Otsuji, Yoko ;

Nagai, Hiroko ;

Sundaram, Krithika ;

El-Kabbani, Ossama ;

Toyooka, Naoki ;

Ohta, Shozo ;

Hara, Akira .

JOURNAL OF NATURAL PRODUCTS, 2012, 75 (04) :716-721

[30] A surface on the androgen receptor that allosterically regulates coactivator binding [J].

Estebanez-Perpina, Eva ;

Arnold, Alexander A. ;

Nguyen, Phuong ;

Rodrigues, Edson Delgado ;

Mar, Ellena ;

Bateman, Raynard ;

Pallai, Peter ;

Shokat, Kevan M. ;

Baxter, John D. ;

Guy, R. Kiplin ;

Webb, Paul ;

Fletterick, Robert J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (41) :16074-16079

← 1 2 3 4 5 6 7 8 →